Enzalutamide

Contraindicated

Enzalutamide Colchicine Colcrys Explained Altered (increased/reduced) colchicine exposure and an increased risk of colchicine toxicity Details Enzalutamide Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Enzalutamide Fostemsavir Rukobia Reduced temsavir (the active moiety of fostemsavir) exposure and possible loss of virologic response Details Enzalutamide Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Enzalutamide Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Enzalutamide Lurasidone Latuda Reduced lurasidone exposure Details Enzalutamide Nifedipine Adalat® Reduced NIFEdipine exposure and reduced efficacy of NIFEdipine Details

Major

Enzalutamide Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Enzalutamide Abametapir Explained Increased exposure of CYP3A4 substrate Details Enzalutamide Clindamycin ANTIROBE Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Enzalutamide Buprenorphine Belbuca Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Enzalutamide Relugolix Orgovyx Explained Increased relugolix exposure Details Enzalutamide Abemaciclib Verzenio Explained Decreased abemaciclib plasma concentration Details Enzalutamide Acalabrutinib Calquence Reduced acalabrutinib exposure Details Enzalutamide Alpelisib Piqray Reduced alpelisib exposure and reduced efficacy of alpelisib Details Enzalutamide Apixaban Eliquis Explained Altered apixaban exposure Details Enzalutamide Apremilast Otezla Reduced apremilast exposure and an reduced efficacy of apremilast Details Enzalutamide Aripiprazole Injection Abilify Reduced ARIPiprazole exposure Details Enzalutamide Asciminib Scemblix Reduced asciminib exposure and reduced efficacy of asciminib Details Enzalutamide Atogepant Qulipta Reduced atogepant exposure Details Enzalutamide Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Enzalutamide Avatrombopag Doptelet Decreased avatrombopag exposure Details Enzalutamide Belumosudil Rezurock Explained Reduced belumosudil exposure and reduced efficacy of belumosudil Details Enzalutamide Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Enzalutamide Abiraterone Abirtega Increased enzalutamide exposure and reduced abiraterone exposure Details Enzalutamide Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Enzalutamide Amlodipine Amvaz® Reduced amLODIPine exposure Details Enzalutamide Axitinib Inlyta Reduced axitinib exposure Details Enzalutamide Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Enzalutamide Bortezomib Boruzu Reduced bortezomib exposure Details Enzalutamide Bosutinib Bosulif Reduced bosutinib exposure and reduced efficacy of bosutinib Details Enzalutamide Brexpiprazole Rexulti Reduced brexpiprazole exposure Details Enzalutamide Brigatinib Alunbrig Reduced brigatinib efficacy Details Enzalutamide Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Enzalutamide Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Enzalutamide Capmatinib Tabrecta Decreased capmatinib exposure and reduction of antitumor activity Details Enzalutamide Clindamycin Injection ANTIROBE Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Enzalutamide Clindamycin Topical C/T/S® Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Enzalutamide Clindamycin Vaginal Cleocin Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Enzalutamide Cobimetinib Cotellic Decreased cobimetinib plasma concentrations Details